Luxendo develops and internationally markets Single Plane Illumination Microscopes (SPIM) for biomedical research. The company raised additional funding as an extension to its Series A, bringing the round to €8m. The extension was led by Life Science Partners (LSP) and included EMBL Ventures and EMBL Enterprise Management Technology Transfer. Luxendo intends to use the funds to expand its international sales and marketing team. Founded in October 2015 as a spin‑out of the European Molecular Biology Laboratory, the company is based in Heidelberg, Germany and is led by CEO Andreas Pfuhl. Its products include the MuVi‑SPIM for fast 3D imaging of living objects and whole specimens without sample rotation, and the InVi‑SPIM, designed for extremely gentle handling and fast 3D imaging of cell cultures and developing embryonic samples. Luxendo was launched by the European Molecular Biology Laboratory (EMBL) and EMBLEM Technology Transfer in Heidelberg, Germany. The company will manufacture and sell advanced Single Plane Illumination Microscopes (SPIM) originally developed at EMBL by Lars Hufnagel and his team. SPIM combines optical sectioning with multiple-view imaging to observe tissues and living organisms with high resolution. Compared to conventional microscopy, the SPIM technology allows for significantly reduced sampling times (factor 1000x), higher resolution and markedly reduced damaging side effects on living specimens. Luxendo closed a €6M Series A financing to support its commercial activities.

Total raised

$15M

Funding rounds

2

Latest round

Series A

Latest activity

Jan 2017